The medical equipment maker also approved a $1 billion share buyback program following record fiscal 2026 results.
STERIS plc projected fiscal 2027 revenue growth of 7%-8% and earnings per share between $11.10 and $11.30. The guidance follows a record fiscal 2026, where revenue rose 9% and adjusted EPS grew 10% despite an 80 basis point headwind from currency fluctuations.
In fiscal 2026, the company reported 7% organic revenue growth on a constant currency basis. The board also authorized a $1 billion share repurchase program, signaling confidence in future cash flow and profitability.
Management highlighted strong performance across segments, though currency impacts slightly tempered overall growth.